Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions

Solveig K. Sieberts1✉, Thanneer M. Perumal1, Minerva M. Carrasquillo2, Mariet Allen2, Joseph S. Reddy3, Gabriel E. Hoffman2,4, Kristen K. Dang5, John Calley1, Philip J. Ebert3, James Eddy1, Xue Wang2, Anna K. Greenwood4, Sara Mostafavi6,7,8, The CommonMind Consortium (CMC)*, The AMP-AD Consortium*, Larsson Omberg1, Mette A. Peters1, Benjamin A. Logsdon2, Philip L. De Jager9, Nilüfer Ertekin-Taner2,10 & Lara M. Mangravite1✉

The availability of high-quality RNA-sequencing and genotyping data of post-mortem brain collections from consortia such as CommonMind Consortium (CMC) and the Accelerating Medicines Partnership for Alzheimer’s Disease (AMP-AD) Consortium enable the generation of a large-scale brain cis-eQTL meta-analysis. Here we generate cerebral cortical eQTL from 1433 samples available from four cohorts (identifying >4.1 million significant eQTL for >18,000 genes), as well as cerebellar eQTL from 261 samples (identifying 874,836 significant eQTL for >10,000 genes). We find substantially improved power in the meta-analysis over individual cohort analyses, particularly in comparison to the Genotype-Tissue Expression (GTEx) Project eQTL. Additionally, we observed differences in eQTL patterns between cerebral and cerebellar brain regions. We provide these brain eQTL as a resource for use by the research community. As a proof of principle for their utility, we apply a colocalization analysis to identify genes underlying the GWAS association peaks for schizophrenia and identify a potentially novel gene colocalization with lncRNA RP11-677M14.2 (posterior probability of colocalization 0.975).

Introduction

Defining the landscape of genetic regulation of gene expression in a tissue-specific manner is useful for understanding both normal gene regulation and how variation in gene expression can alter disease risk. In the latter case, a variety of approaches now leverage the association between genetic variants and gene expression changes, including colocalization analysis1−7, transcriptome-wide association studies (TWAS)8,9, and gene regulatory network inference.10−16.

There has been a relative lack of expression quantitative trait loci (eQTL) studies from the brain. Because of the more accessible nature of tissues such as blood or lymphoblastoid cell lines (LCLs), much of the large-scale identification of expression quantitative trait loci (eQTL) has occurred in these tissues.17−20. For most other tissues, obtaining samples for RNA sequencing (RNA-seq) requires invasive biopsy, and brain tissues are typically only available in post-mortem brain samples. One effort, the Genotype-Tissue Expression (GTEx) project11−12, has profiled a broad range of tissues (42 distinct) for eQTL discovery, however, samples sizes in brain have been small.
(typically 100–150). Recently, efforts to understand gene expression changes in neuropsychiatric23–26 and neurodegenerative diseases27–34 have generated brain RNA-seq from disease and normal tissue, as well as genome-wide genotypes. These analyses have found little evidence for widespread disease-specific eQTL, as well as high cross-cohort overlap34,35, meaning that most eQTL detected are disease-condition independent. This implies that meta-analysis across disease-based cohorts will capture eQTL which are unconfounded by disease state despite differences in disease ascertainment of the samples, and leverages thousands of available samples to produce a well-powered brain eQTL resource for use in downstream research.

Here we generate a public eQTL resource from cerebral cortical tissue using 1433 samples from 4 cohorts from the CommonMind Consortium (CMC)23,24,26 and the Accelerating Medicines Partnership for Alzheimer's Disease (AMP-AD) Consortium35,36, as well as from cerebellum using 261 samples from AMP-AD. We show that eQTL discovered in GTEx, which consists of control individuals (without disease) only, are replicated in this larger brain eQTL resource. We further show widespread differences in regulation between cerebral cortex and cerebellum. To demonstrate one example of the utility of these data, we apply a colocalization analysis, which seeks to identify expression traits whose eQTL association pattern appears to co-occur at the same loci as the clinical trait association, to identify putative genes underlying the GWAS association peaks for schizophrenia40.

### Results

We generated eQTL from the publicly available AMP-AD (ROSMAP27,28,35,37, Mayo RNAseq29,38–40) and CMC23,24,26 (MSSM-Penn-Pitt24,26, HBCC26) cohorts with available genotypes and RNA-seq data, using a common analysis pipeline (Supplementary Table 1) (https://www.synapse.org/#!Synapse:syn17015233). Analyses proceeded separately by cohort. Briefly, the RNA-seq data were normalized for gene length and GC content prior to adjustment for clinical confounders, processing batch information, and hidden confounders using Surrogate Variable Analysis (SVA)41. Genes having at least 1 count per million (CPM) in at least 50% of samples were retained for downstream analysis (Supplementary Table 2). Genotypes were imputed to the HaploType Reference Consortium (HRC) reference panel42. eQTL were generated adjusting for diagnosis (AD, control, other for AMP-AD cohorts and schizophrenia, control, other for CMC cohorts) and principal components of ancestry separately for ROSMAP, Mayo temporal cortex (TCX), Mayo cerebellum (CER), MSSM-Penn-Pitt, and HBCC. For HBCC, which had a small number of samples derived from infant and adolescents, we excluded samples with age-of-death less than 18, to limit heterogeneity due to differences between the mature and developing brain.

We then performed a meta-analysis using the eQTL from cortical brain regions from the individual cohorts (dorsolateral prefrontal cortex (DLPFC) from ROSMAP, MSSM-Penn-Pitt, and HBCC and TCX from Mayo). The meta-analysis identifies substantially more eQTL than the individual cohorts (Table 1, Fig. 1). There is a strong relationship between the sample size in the individual cohorts and meta-analysis and the number of significant eQTL and genes with eQTL (Fig. 1b,c). Notably, the meta-analysis identified significant eQTL (at FDR ≤ 0.05) in >1000 genes for which no eQTL were observed in any individual cohort. Additionally, we find significant eQTL for 18,295 (18,433 when considering markers with minor allele frequency (MAF) down to 1%) of the 19,392 1000 genes for which no eQTL were observed in any individual cohort. Additionally, we find significant eQTL within our cortical and cerebellar eQTL of eQTL derived from the two GTEx cerebellar brain regions (cerebellum and cerebellar hemisphere) is consistently lower than for other brain regions represented in GTEx. However, replication of GTEx cerebellar eQTL is high when compared to the cerebellar eQTL generated in this analysis from the Mayo Clinic CER samples. We also performed the reverse comparison, by examining the replication of our eQTL in those region-specific eQTL identified in GTEx. Unsurprisingly, the replication levels were substantially lower, due to

| Cohort         | Cis eQTL# | Unique Genes with Signif. eQTL | eQTL (Genes) not Present in GTEx* | Meta-eQTL (Genes) not found in Cohort | Genes w/o eQTL in CMC, ROSMAP, HBCC or Mayo TCX |
|---------------|-----------|-------------------------------|-----------------------------------|---------------------------------------|-----------------------------------------------|
| ROSMAP        | 2,472,838 | 13,543                        | 2,205,025 (7,829)                 | 2,103,711 (5,079)                     |                                               |
| Mayo TCX      | 712,401   | 8,838                         | 480,507 (4,439)                   | 3,483,381 (9,591)                     |                                               |
| CMC           | 1,322,680 | 12,641                        | 1,062,830 (7,206)                 | 2,948,886 (5,897)                     |                                               |
| HBCC          | 577,512   | 9,112                         | 379,732 (4,645)                   | 3,614,448 (9,337)                     |                                               |
| Meta-Analysis  | 4,142,776 | 18,295                        | 3,800,208 (11,395)                | 1,042                                 |                                               |

Table 1. eQTL results from individual cohorts and meta-analysis. *SNP-gene pairs with MAF ≥ 0.02 and FDR < 0.05. **GTEx (v7) Anterior Cingulate Cortex, Cortex or Frontal Cortex. ***Additional 36,352 (138) eQTL (Genes) with 0.01 ≤ MAF < 0.02.
the lower power in the GTEx analyses. Replication rates were not substantially changed by using GTEx eQTL discovered using our less conservative approach.

Additionally, we compared our eQTL to a publically available fetal brain eQTL resource and found good replication of these eQTL as well (estimated replication rate $\pi_1 = 0.909$ for the cortical meta-analysis, and $\pi_1 = 0.861$ for cerebellum), though somewhat lower than the replication observed in the GTEx cohorts, which are comprised of adult-derived samples.

Finally, as a proof of concept, we performed a colocalization analysis between our eQTL meta-analysis and the Psychiatric Genomics Consortium (PGC) v2 schizophrenia GWAS summary statistics. Seventeen genes showed posterior probability of colocalization using coloc ($PP(H_4) > 0.7$) (Table 3), with 3 showing $PP(H_4) > 0.95$. FURIN, ZNF823, and RP11-677M14.2 have previously been identified as candidates through colocalization and have recently been shown to reduce brain-derived neurotrophic factor (BDNF) maturation and secretion when inhibited by miR-338-3p. ZNF823 has been identified in previous colocalization analyses. RP11-677M14.2, a lncRNA located inside NRGN, while not previously identified through colocalization analysis, has been shown to be down-regulated in the amygdala of schizophrenia patients. NRGN does not appear to show eQTL colocalization ($PP(H_4) = 0.006$), instead showing strong evidence for the eQTL and GWAS associations occurring independently ($PP(H_4) = 0.994$). Two additional strong colocalizations THOC7 ($PP(H_4) = 0.943$) and FAM85B ($PP(H_4) = 0.948$) show other potential candidates in the region (Supplementary Table 3). At the THOC7 locus, the competing gene, C3orf49 shows slightly lower strength for colocalization ($PP(H_4) = 0.943$), and the associations do not appear to be independent ($R^2 = 0.979$). At the FAM85B locus, the competing pseudo gene FAM86B3P shows substantially lower evidence for colocalization ($PP(H_4) = 0.513$) and in this case too, the associations appear to be non-independent ($R^2 = 0.902$).
Discussion

Using resources generated in the AMP-AD and CMC consortia, we have generated a well-powered brain eQTL resource for use by the scientific community. Unsurprisingly, we see a strong relationship between the number of significant eQTL, as well as genes with significant eQTL, and sample size using analyses from the individual cohorts as well as the meta-analysis of those cohorts. This result has previously been shown for lower sample sizes\(^1\). We also show higher replication of GTEx eQTL in the meta-analysis relative to the individual cohorts.

These conclusions appear to be independent of methodological differences between our analysis and the one done by GTEx. Notably, we find significant eQTL for nearly every gene in our analysis, which include all but very lowly expressed genes (less than 1 cpm in more than 50% of samples). The wide discovery of eQTL is potentially beneficial for analyses utilizing these results, such as colocalization analysis or TWAS imputation, because more genes with significant eQTL means more genes can be evaluated with these approaches. Because we have discovered eQTL for most genes, further increasing sample size will not substantially increase the number of genes with significant eQTL. However it is likely that the number of significant eQTL associations within each gene would continue to increase, which may include additional associations tagging the same regulator or independent associations tagging weaker regulators, along with the accuracy of estimated effect sizes. This will result in a more accurate landscape of regulatory association, which will improve the ability to fine-map causal regions, and colocalize eQTL signal with clinical traits of interest. Thus, it will be valuable to continue to update this meta-analysis with additional data from these consortia and other resources as they become available, and continue to improve this resource as future data permits. Future work may also focus on using well-powered analysis to study the landscape of causal variation and co-variation in gene regulation.

We found distinct eQTL patterns across cerebral cortical and cerebellar brain regions in our resource. Specifically, comparison of eQTL from our resource with those from GTEx shows high replication for the majority of brain regions. However, cerebellar regions show consistently lower replication with the cerebral cortical eQTL generated here. In contrast, the cerebellar eQTL generated from the Mayo Clinic study replicate GTEx cerebellar eQTL at a substantially higher rate, suggesting a different pattern of regulatory variation affecting expression in cerebellum versus other brain regions. Indeed, epigenomic analyses show substantial differences between cerebellar and cerebral cortical regions\(^1\), particularly in methylation patterns, which could drive different eQTL association patterns. This is further corroborated by the observation of substantial coexpression differences between cerebellar and other brain regions\(^5\). These effects could be due to differences in cell type composition, with cerebellar regions consisting of substantially more neurons than other brain regions\(^5\). This is supported by a gene enrichment analysis of genes showing different eQTL association patterns between cerebellum and cortex, which showed that many of the top gene sets were neuron or signaling related (Supplementary Table 4). One recent report suggests that there are also widespread differences in histone modifications within cell types derived from cerebellar and cortical regions\(^6\), though this effect had not been noted in other studies. In particular, Ma et al.\(^7\) observed that both neuronal and non-neuronal cell types show differing histone modifications across tissue of origin. Further work is necessary to confirm this finding and to develop models to deconvolve the cell-type specific regulatory effects in different brain regions\(^8\), however our analysis demonstrates that this meta-analysis is representative of eQTL across the majority of brain regions, with the exception of cerebellum. Future meta-analytic analyses may also cast a wider net in terms of brain regions included.

---

**Table 3.** Top colocalized genes as inferred between meta-analysis eQTL and the PGC2 schizophrenia GWAS. *eQTL Peak Location is ± 1 Mb around the gene location. **SNP showing the highest PP(H4) between the gene and GWAS trait. ***At Posterior Probability of Colocalization ≥ 0.5.

| Gene  | eQTL Peak Location* Chr | Start | End  | \(N_{SNP}\) | GWAS eQTL | Min(p-value) | Best Colocalized SNP** | Posterior Probability of Colocalization | Additional Candidates at this Locus*** |
|-------|-------------------------|-------|------|-------------|------------|--------------|----------------------|----------------------------------------|--------------------------------------|
| RERE  | 1                       | 7412665 | 9877280 | 4905       | 2.72E-09   | 2.28E-21     | rs301792 0.730         |                                        |                                      |
| PTTRU | 1                       | 28563084 | 30653243 | 4099       | 1.28E-09   | 4.42E-10     | rs1499232 0.890         |                                        |                                      |
| FOXN2 | 2                       | 47542228 | 49606348 | 5437       | 1.66E-06   | 8.85E-45     | rs79073127 0.782        |                                        |                                      |
| C3orf49 | 3                  | 62805378 | 64834213 | 4906       | 2.58E-08   | 1.10E-13     | rs832187 0.820         | Yes                                    |                                      |
| THOC7 | 3                       | 62819766 | 64848612 | 4886       | 2.58E-08   | 2.21E-39     | rs832190 0.943         | Yes                                    |                                      |
| TBCD19 | 4                  | 25578209 | 27755954 | 4432       | 7.44E-07   | 7.85E-07     | rs6825268 0.900        |                                        |                                      |
| CLCN3 | 4                       | 169533866 | 17148421 | 4956       | 1.02E-08   | 1.91E-09     | rs10520163 0.768       |                                        |                                      |
| PPP1R18 | 6               | 29644275 | 31655438 | 1055       | 1.16E-19   | 5.32E-31     | rs2522607 0.827        | Yes                                    |                                      |
| LINC00222 | 6   | 108073451 | 110091064 | 3600       | 3.37E-08   | 1.63E-07     | rs9998171 0.852        |                                        |                                      |
| FAM85B | 8                       | 8089567 | 9084121 | 3725       | 2.03E-08   | 5.63E-31     | rs2980439 0.948        | Yes                                    |                                      |
| ENDOG | 9                       | 130581300 | 132584048 | 3294       | 1.92E-06   | 6.90E-62     | rs6478554 0.721        | Yes                                    |                                      |
| RP11-677M14.2 | 11 | 123614560 | 125616016 | 5253       | 3.68E-12   | 1.50E-09     | rs5566136 0.975        |                                        |                                      |
| FURIN | 15                      | 90414642 | 92466544 | 4767       | 2.30E-12   | 1.29E-20     | rs4702 0.999          |                                        |                                      |
| CNOT1 | 16                      | 57553885 | 59662867 | 5364       | 1.15E-08   | 1.16E-06     | rs12325245 0.862       |                                        |                                      |
| ELAC2 | 17                      | 11896953 | 13921426 | 5651       | 2.84E-06   | 3.90E-106    | rs1045464 0.856        |                                        |                                      |
| ZNF823 | 19               | 10832190 | 12840037 | 3844       | 1.57E-06   | 5.38E-10     | rs3095917 0.961        |                                        |                                      |
| PTK6  | 20                      | 61160251 | 62960229 | 4527       | 4.03E-08   | 1.09E-26     | rs427230 0.897         |                                        |                                      |

---

*Table 3.** Top colocalized genes as inferred between meta-analysis eQTL and the PGC2 schizophrenia GWAS. *eQTL Peak Location is ± 1 Mb around the gene location. **SNP showing the highest PP(H4) between the gene and GWAS trait. ***At Posterior Probability of Colocalization ≥ 0.5.
The replication of fetal eQTL, while significant, is somewhat lower than the replication of adult eQTL represented in GTEx. This may be due to multiple factors. The fetal eQTL analysis was generated from brain homogenate, rather than dissected brain regions, though the lower replication likely also reflects broad transcriptional differences between developing and mature brain. These transcriptional differences may also explain why we find substantially more eQTL than a recently published, similarly sized eQTL analysis which uses samples from across developmental and adult timepoints and, why this meta-analysis shows higher replication of GTEx eQTL.

Previous studies report a lack of widespread disease-specific eQTL observed in schizophrenia (CMC) and Alzheimer’s (ROSMAP). In accordance, we find a strong overlap among eQTL across disparate disease samples, particularly those with neuropsychiatric and neurodegenerative disorders, as well as normal individuals from these and other cohorts such as GTEx. This suggests that disease-specific eQTL, if they exist, are likely few in number and/or small in effect size, relative to condition-independent eQTL in general. If they do exist, disease-specific eQTL discovery may be successful in more targeted analyses or with larger sample sizes or meta-analyses, but was not explored for the purpose of this general resource. Thus, the heterogeneous samples derived from different disease-based cohorts can be meta-analyzed to create a general-purpose brain eQTL resource representing adult gene regulation, despite comprising samples with different disease backgrounds, along with normal controls. Therefore, these eQTL will be useful both within and outside these specific disease contexts. For example, since these eQTL are not disease specific they may be used to understand healthy gene expression regulation in the brain, as well as to infer colocalization of eQTL signatures with disease risk for any disease whose tissue etiology is from the brain, since these signatures are reflective of normal brain regulation. It should be stated that while many eQTL are not disease specific, i.e., they are identified under various central nervous system (CNS) disease diagnoses and in control brains, they may still contribute to common CNS diseases as previously demonstrated. While we have demonstrated proof-of-concept colocalization analysis with a previously published schizophrenia GWAS, these eQTL are a broadly useful resource for studying neuropsychiatric and neurodegenerative disorders, as well as for understanding the landscape of gene regulation in brain.

Methods

RNA-seq Re-alignment. For the CMC studies (MSSM-Penn-Pitt, HBCC), RNA-seq reads were aligned to GRCh37 with STAR v2.4.0.gv using annotations from ENSEMBL v75. For the AMP-AD studies (ROSMAP, Mayo RNAseq), Picard v2.2.4 (https://broadinstitute.github.io/picard/) was used to generate FASTQ files from the available BAM files, using the Picard SamToFastq function. Picard SortSam was first applied to ensure that R1 and R2 reads were correctly ordered in the intermediate SAM file before converting to FASTQ. The converted FASTQs were aligned to the GENCODE24 (GRCh38) reference genome using STAR v2.5.1b, with twoPassMode set as Basic. Gene counts were computed for each sample by STAR by setting quantMode as GeneCounts.

RNA-seq normalization. To account for differences between samples, studies, experimental batch effects and unwanted RNA-seq-specific technical variations, we performed library normalization and covariate adjustments for each study separately using fixed/mixed effects modeling. A mixed effect model was required to jointly normalize both tissues from the Mayo cohort. All other cohorts contained only one tissue, so a fixed effect model was used. The workflow consisted of the following steps:

1. **Gene filtering**: Out of ~56K aligned and quantified genes, only genes showing at least modest expression were used in this analysis. Genes that were expressed more than 1 CPM (read Counts Per Million total reads) in at least 50% of samples in each tissue and diagnosis category were retained for analysis. Additionally, genes with available gene length and percentage GC content from BioMart December 2016 archive were subselected from the above list. This resulted in approximately 14K to 16K genes in each study.

2. **Calculation of normalized expression values**: Sequencing reads were then normalized in two steps. First, conditional quantile normalization (CQN) was applied to account for variations in gene length and GC content. In the second step, the confidence of sampling abundance was estimated using a weighted linear model using the voom-limma package in bioconductor. The normalized observed read counts, along with the corresponding weights, were used in the following steps.

3. **Outlier detection**: Based on normalized log2(CPM) of expression values, outlier samples were detected using principal component analysis (PCA) and hierarchical clustering. Samples identified as outliers using both the above methods were removed from further analysis.

4. **Covariate imputation**: Before identifying associated covariates, important missing covariates were imputed. Principally, post-mortem interval (PMI), or the latency between death and tissue collection, which is frequently an important covariate for the analysis of gene expression from post-mortem brain tissue, was imputed for a portion of samples in Mayo RNAseq data for which true values were unavailable. Genomic predictors of PMI were estimated using ROSMAP and MESS (an additional RNA-seq study available through AMP-AD) samples and were used to impute missing values as necessary.

5. **Covariate identification**: Normalized log2(CPM) counts were then explored to determine which known covariates (both biological and technical) should be adjusted. Except for the HBCC study, we used a stepwise (weighted) fixed/mixed effect regression modeling approach to select the relevant covariates having a significant association with gene expression. Here, covariates were sequentially added to the model if they were significantly associated with any of the top principal components, explaining more than 1% of variance of expression residuals. For HBCC, we used a model selection based on Bayesian information criteria (BIC) to identify the covariates that improve the model in more than 50% of genes.
6. **SVA adjustments**: After identifying the relevant known confounders, hidden-confounders were identified using the Surrogate Variable Analysis (SVA)\(^41\). We used a similar approach as previously defined\(^24\) to find the number of surrogate variables (SVs), which is more conservative than the default method provided by the SVA package in R\(^86\). The basic idea of this approach is that for an eigenvector decomposition of permuted residuals each eigenvalue should explain an equal amount of the variance. By the nature of eigenvalues, however, there will always be at least one that exceeds the expected value. Thus, from a series of 100 permutations of residuals (white noise) we identified the number of covariates as shown in Supplementary Table 1. We applied the “irw” (iterative re-weighting) version of SVA to the normalized gene expression matrix, along with the covariate model described above to obtain residual gene expression for eQTL analysis.

7. **Covariate adjustments**: We performed a variant of fixed/mixed effect linear regression, choosing mixed-effect models when multiple tissues or samples were available per individual, as shown above: gene expression ~ Diagnosis + Sex + covariates + (1|Donor), where each gene was linearly regressed independently. Here Donor (individual) was modeled as a random effect when multiple tissues from the same individual were present. Observation weights (if any) were calculated using the voom-limma\(^62,63\) pipeline, which has a net effect of up-weighting observations with inferred higher precision in the linear model fitting process to adjust for the mean-variance relationship in RNA-seq data. The diagnosis component was then added back to the residuals to generate covariate-adjusted expression for eQTL analysis.

This workflow was applied separately for each study. For the AMP-AD studies, gene locations were lifted over to GRCh37 for comparison with the genotype imputation panel (described below). For HBCC, samples with age <18 were excluded prior to analysis. Supplementary Table 1 shows the covariates and surrogate variables identified in each study.

**AD diagnosis harmonization.** Prior to RNA-seq normalization, we harmonized the LOAD definition across AMP-AD studies. AD controls were defined as patients with a low burden of plaques and tangles, as well as lack of evidence of cognitive impairment. For the ROSMAP study, we defined AD cases to be individuals with a Braak\(^67\) greater than or equal to 4, CERAD score\(^68\) less than or equal to 2, and a cognitive diagnosis of probable AD with no other causes (cogdx = 4), and controls to be individuals with Braak less than or equal to 3, CERAD score greater than or equal to 3, and cognitive diagnosis of ‘no cognitive impairment’ (cogdx = 1). For the Mayo Clinic study, we defined disease status based on neuropathology, where individuals with Braak score greater than or equal to 4 were defined to be AD cases, and individuals with Braak score less than or equal to 3 were defined to be controls. Individuals not meeting “AD case” or “control” criteria were retained for analysis, and were categorized as “other” for the purposes of RNA-seq adjustment.

**Genotype QC and imputation.** Genotype QC was performed using PLINK v1.9\(^99\). Markers with zero alternate alleles, genotyping call rate ≤ 0.98, Hardy-Weinberg p-value < 5e−5 were removed, as well as individuals with genotyping call rate < 0.90. Samples were then imputed to HRC (Version r1.1 2016)\(^85\) as follows: marker positions were lifted-over to GRCh37, if necessary. Markers were then aligned to the HRC loci using HRC-1000G-check-bim-v4.2 (http://www.well.ox.ac.uk/~wrayner/tools/), which checks the strand, alleles, position, reference/alternate allele assignments and frequencies of the markers, removing A/T & G/C single nucleotide polymorphisms (SNPs) with minor allele frequency (MAF) > 0.4, SNPs with differing alleles, SNPs with > 0.2 allele frequency difference between the genotyped samples and the HRC samples, and SNPs not in the reference panel. Imputation was performed via the Michigan Imputation Server\(^70\) using the Eagle v2.3\(^71\) phasing algorithm. Imputation was done separately by cohort and by chip within cohort, and markers with R\(^2\) ≥ 0.7 and minor allele frequency (MAF) ≥ 0.01 (within cohort) were retained for analysis.

**Genetic ancestry inference.** GEMTOOLs\(^72\) was used to infer ancestry and compute ancestry components separately by cohort. The GEMTOOLS algorithm uses a significance test to estimate the number of eigenvectors (ancestry components) necessary to represent the variability in the data\(^73\). For each cohort, we used the top components as estimated by the GEMTOOLs algorithm, which resulted in some variation in the number of components selected. For MSSM-Penn-Pitt and HBCC, which are multi-ethnic cohorts, only Caucasian samples were retained for eQTL analysis.

**eQTL analysis.** eQTL were generated separately in each cohort and tissue using MatrixEQTL\(^74\) adjusting for harmonized Diagnosis and inferred Ancestry components using “cis” gene-marker comparisons: Expression ~ Genotype + Diagnosis + PC\(_G\) + … + PC\(_n\), where PC\(_k\) is the k\(^{th}\) ancestry component, using Expression variables which were previously covariate adjusted as described above. Here we define “cis” as ± 1 MB around the gene, and GRCh37 gene locations were used for consistency with the marker imputation panel. Meta-analysis was performed via fixed-effect model\(^75\) using an adaptation of the metareg function in the gap package in R. In order to assess potential inflation of Type 1 error, we performed 5 permutations of the gene expression values, relative to genotype and ancestry components, within diagnosis for each cohort, and repeated the regression analyses as described above. For each of the 5 iterations of permutation, a meta-analysis was then performed across the 4 cohorts. We found that Type 1 error was well controlled (Fig. 1a). Given that multiple tissues were present, we also evaluated a random-effect model, but found substantially deflated p-values (less significant) in the permutations, relative to the expected distribution, suggesting that this model is over-conservative.

**Comparison with GTEx and fetal eQTL.** Full summary statistics for the GTEx v7\(^21\) eQTL for all available brain regions were obtained from the GTEx Portal (https://gtexportal.org/), and fetal eQTL were obtained from
Figshare\textsuperscript{76}. For each replication comparison (e.g. meta-analysis vs GTEx or meta-analysis vs. fetal eQTL), only markers and genes present in both the external eQTL and our analysis were retained for comparison. As this was done separately for GTEx and for the fetal eQTL resource, the list of genes and SNPs varies slightly for each comparison. The replication rate was estimated as the $\pi$ statistic using the \texttt{qvalue} package\textsuperscript{77} in R as follows: we extracted the meta-analysis p-values for all SNP-gene pairs, which were significant in GTEx at FDR $\leq 0.05$. We then applied the \texttt{qvalue} command to the meta-analysis p-values to generate $\hat{\pi} = 1 - \hat{p}$, which corresponds to estimated proportion of non-null p-values\textsuperscript{77}. The ‘smoother’ option was used to estimate $\hat{\pi}$ as a function of the tuning parameter $A$ as it approaches 1. The variance around this estimate is relatively small (see Supplementary Figures 1 and 2 for example) and does not materially affect the observations in this manuscript.

Conversely, we estimated the replication rate of significant meta-analysis eQTL SNP-gene pairs in GTEx. Analogous methods were used to estimate all other replication rates. For the purposes of reporting the total number of eQTL not present in GTEx, and genes without eQTL in GTEx (Table 1), we have included genes and SNP-gene pairs not present in GTEx in the count, however this accounts for a relatively small proportion of the difference (472,995 eQTL and 1481 genes).

### GTEx eQTL generation

In order to verify that the observed power increase and replication imbalances were not due to methodological differences between this manuscript and those performed by GTEx, we obtained access to the GTEx v7 data, and generated eQTL for cortex, anterior cingulate cortex, and frontal cortex using our approach. We used gene expression and imputed genotypes as provided, as well as the provided covariates, which included 3 ancestry covariates, 14-15 surrogate variable covariates, sex and platform. We then repeated the comparisons with the meta-analysis described in the previous section, using a MAF cutoff of 0.03, which best appeared to control Type 1 error, as observed by permutation between genotype and gene expression, while maximizing the number of significant eQTL in the true data. Results did not change materially.

### Pathway analysis of cerebellar eQTL genes

In order to identify whether genes showing cerebellar-specific eQTL patterns showed any biological coherence, we performed a pathway analysis as follows. For genes with at least 5 significant cerebellar eQTL, we computed the Spearman correlation of effect-size between cerebellum eQTL and cortical eQTL for the loci that were significant in cerebellum. We then selected genes for which the effect-sizes did not show positive correlation (Spearman’s $\rho < 0.1$) between the two tissues as showing different eQTL association patterns across the gene and performed a pathway analysis with GO biological processes Fisher’s exact test. Note that due to the (power-mediated) greater detection of eQTL in cortex, we did not perform the reverse comparison. The results were relatively robust to the choice of minimum number of significant eQTL, correlation cutoff, and choice of correlation statistic (Spearman vs Pearson).

### Coloc analysis

We applied Approximate Bayes Factor colocalization (coloc.abf)\textsuperscript{77} from the coloc R package to the summary statistics from the PGC2 Schizophrenia GWAS\textsuperscript{36} downloaded from the PGC website (http://pgc.unc.edu), and the summary statistics from the eQTL meta-analysis. Each gene present in the meta-analysis was compared to the GWAS in turn, and suggestive and significant GWAS peaks with $p$-value $< 5\times 10^{-6}$ were considered for analysis.

### Data availability

Data for the ROSMAP\textsuperscript{37} and Mayo cohorts\textsuperscript{40} are available through the AMP-AD Knowledge Portal\textsuperscript{31}. Data for the MSSM-Penn-Pitt and HBCCC cohorts are available through the CommonMind Knowledge Portal\textsuperscript{39}.

eQTL results for the ROSMAP\textsuperscript{38}, Mayo TCX\textsuperscript{42}, Mayo CER\textsuperscript{39} and cortical meta-analysis\textsuperscript{41} are available through the AMP-AD Knowledge Portal. These results include SNP (location, rsid, alleles, and allele frequency) and gene (location, gene symbol, strand and biotype) information, as well as estimated effect size (beta), statistic (z), $p$-value, FDR, and expression-increasing allele.

### Code availability

An R package with all code for the gene expression normalization is available at https://github.com/Sage-Bionetworks/ampad-diffexp. All other analyses were generated using packages publicly available from their respective authors.

Received: 28 May 2019; Accepted: 24 August 2020; Published online: 12 October 2020

### References

1. Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nat. Genet.* **48**, 481–487 (2016).
2. Nica, A. C. et al. Candidate Causal Regulatory Effects by Integration of Expression QTLs with Complex Trait Genetic Associations. *PLoS Genet.* **6**, e1000895 (2010).
3. Ongen, H. et al. Estimating the causal tissues for complex traits and diseases. *Nat. Genet.* **49**, 1676–1683 (2017).
4. Chun, S. et al. Limited statistical evidence for shared genetic effects of eQTLs and autoimmune-disease-associated loci in three major immune-cell types. *Nat. Genet.* **49**, 600–605 (2017).
5. Hormozdiari, F., Kostem, E., Kang, E. Y., Pasaniuc, B. & Eskin, E. Identifying Causal Variants at Loci with Multiple Signals of Association. *Genetics* **198**, 497–508 (2014).
6. He, X. et al. Sherlock: Detecting Gene-Disease Associations by Matching Patterns of Expression QTL and GWAS. *Am. J. Hum. Genet.* **92**, 667–680 (2013).
7. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. *PLoS Genet.* **10**, e1004383 (2014).
8. Gamazon, E. R. et al. A gene-based association method for mapping traits using reference transcriptome data. *Nat. Genet.* **47**, 1091–1098 (2015).
9. Barbeira, A. N. et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. Nat. Commun. 9, 1825 (2018).
10. Zhu, J. et al. An integrative genomics approach to the reconstruction of gene networks in segregating populations. Cytogenet. Genome Res. 105, 363–74 (2004).
11. Schadt, E. et al. Mapping the Genetic Architecture of Gene Expression in Human Liver. PLoS Biol 6, e107 (2008).
12. Zhu, J. et al. Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat. Genet. 40, 854–61 (2008).
13. Greenawalt, D. M. et al. A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. Genome Res. 21, (2011).
14. Zhang, B. et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer’s disease. Cell 153, 707–20 (2013).
15. Frank, O. et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Science 353, 827–30 (2016).
16. Peters, L. A. et al. A functional genomics predictive network model identifies regulators of inflammatory bowel disease. Nat. Genet. 49, 1457–1449 (2017).
17. Battle, A. et al. Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals. Genome Res 24, 14–24 (2014).
18. Westra, H.-J. et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 45, 1238–1243 (2013).
19. Vosa, U. et al. Unraveling the polygenic architecture of complex traits using blood eQTL meta-analysis. bioRxiv Preprint at, http://biorxiv.org/content/early/2018/10/19/447367/abstract (2018).
20. Qi, T. et al. Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood. Nat. Commun. 9, 2282 (2018).
21. Aguet, F. et al. Genetic effects on gene expression across human tissues. Nature 550, 204–213 (2017).
22. Ardlie, K. G. et al. The Genotype-Tissue Expression (GTEx) pilot analysis: Multisite tissue gene regulation in humans. Science (80-.)
348, 648–660 (2015).
23. CommonMind Consortium Data Release Portal. Synapse https://doi.org/10.7303/syn2759792 (2015).
24. Fumer, M. et al. Gene expression elucidates functional impact of polygenic risk for schizophrenia. Nature Neuroscience 19, 1442–1453 (2016).
25. Wang, D. et al. Comprehensive functional genomic resource and integrative model for the human brain. Science (80-.)
362, eaat8464 (2018).
26. Hoffman, G. E. et al. CommonMind Consortium provides transcriptomic and epigenomic data for Schizophrenia and Bipolar Disorder. Sci. Data 6, 180 (2019).
27. Chibnik, L. B. et al. Susceptibility to neurofibrillary tangles: the role of PTTPRD locus and limited pleiotropy with other neurodegenerative diseases. Mol. Psychiatry 23, 1521 (2017).
28. Mostafavi, S. et al. A molecular network of the aging human brain provides insights into the pathology and cognitive decline of Alzheimer’s disease. Nat. Neurosci. 21, 811–819 (2018).
29. Allen, M. et al. Human whole genome genotype and transcriptome data for Alzheimer’s and other neurodegenerative diseases. Sci. Data 3, 160089 (2016).
30. Wan, Y.W. et al. Meta-Analysis of the Alzheimer’s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models. Cell Rep. 32(2), 107908 (2020).
31. AMP AD Target Discovery Data Portal. Synapse https://doi.org/10.7303/syn2580853 (2015).
32. Allen, M. et al. Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology 79, 221–28 (2012).
33. Zou, F. et al. Brain expression genome-wide association study (eGWAS) identifies human disease-associated variants. PLoS Genet 8, e1002707 (2012).
34. Allen, M. et al. Late-onset Alzheimer disease risk variants mark brain regulatory loci. Neur. Genet. 1, e15 (2015).
35. Ng, B. et al. An xQTL map integrates the genetic architecture of the human brain transcriptome and epigenome. Nat. Neurosci. 20, 1418–1426 (2017).
36. Ripke, S. et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature 511, 421–427 (2014).
37. ROSMAP Study. Synapse https://doi.org/10.7303/syn3219045 (2016).
38. Allen, M. et al. Conserved brain myelination networks are altered in Alzheimer’s and other neurodegenerative diseases. Alzheimers. Dement. 14, 352–366 (2018).
39. Allen, M. et al. Divergent brain gene expression patterns associate with distinct cell-specific tau neuropathology traits in progressive supranuclear palsy. Acta Neurologica 136, 709–727 (2018).
40. Mayo RNAseq Study. Synapse https://doi.org/10.7303/syn5550404 (2016).
41. Leek, J. T. & Storey, J. D. Capturing Heterogeneity in Gene Expression Studies by Surrogate Variable Analysis. Plos Genet 3, e161 (2007).
42. McCarthy, S. A. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279–83 (2016).
43. O’Brien, H. E. et al. Expression quantitative trait loci in the developing human brain and their enrichment in neuropsychiatric disorders. Genome Biol. 19, 198 (2014).
44. Hou, Y. et al. Schizophrenia-associated rs4702 G allele—specific downregulation of FURIN expression by miR-338-3p reduces BDNF production. Schizophr. Res. 199, 176–180 (2018).
45. Dobyns, B. et al. Landscape of Conditional eQTL in Doroslateral Prefrontal Cortex and Co-localization with Schizophrenia GWAS. Am. J. Hum. Genet. 102, 1169–1184 (2018).
46. Paridíñas, A. F. et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50, 381–389 (2018).
47. Liu, Y. et al. Non-coding RNA dysregulation in the amygdala region of schizophrenia patients contributes to the pathogenesis of the disease. Transl. Psychiatry 8, 44 (2018).
48. Lu, A. T. et al. Genetic architecture of epigenetic and neuronal ageing rates in human brain regions. Nat. Commun. 8, 15533 (2017).
49. Davies, M. N. et al. Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol 13, R43 (2012).
50. Hannan, E., Lunnon, K., Schalkwyk, L. & Mill, J. Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. Epigenetics 10, 1024–1032 (2015).
51. Quintavilano, J., Aryee, M. J. & Kaminsky, Z. A. A cell epigenotype specific model for the correction of brain cellular heterogeneity bias and its application to age, brain region and major depression. Epigenetics 8, 290–302 (2013).
52. Negi, S. K. & Guda, C. Global gene expression profiling of healthy human brain and its application in studying neurological disorders. Sci. Rep. 7, 897 (2017).
53. Areveco, F. A. C. et al. Equal numbers of neuronal and nonneuronal cells make the human brain an isometrically scaled-up primate brain. J. Comp. Neuro. 513, 532–541 (2009).
54. Ma, S., Hsich, Y.-P., Ma, J. & Lu, C. Low-input and multiplexed microfluidic assay reveals epigenomic variation across cerebellum and prefrontal cortex. Sci. Adv. 4, eaar8187 (2018).
Acknowledgements

For the ROSMAP and Mayo RNAseq studies, the results published here are in whole or in part based on data obtained from the AMP-AD Knowledge Portal (doi:10.7303/syn2580853). ROSMAP study data were provided by the Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago. Data collection was supported through funding by NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute. Mayo RNA-seq study data were provided by the following sources: The Mayo Clinic Alzheimer’s Disease Genetic Studies, led by Dr. Nilufar Ertekin-Taner and Dr. Steven G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the Mayo Clinic Alzheimer’s Disease Research Center, and the Mayo Clinic Brain Bank. Data collection was supported through funding by NIA grants P50 AG10161, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. Study data includes samples collected through the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinsons Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimers Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer’s Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 1001 to the Arizona Parkinson’s Disease Consortium) and the Michael J. Fox Foundation for Parkinsons Research. This study was in part supported by NIH RF1 AG051504 and R01 AG061796 (NET). For CommonMind, data were generated as part of the CommonMind Consortium supported by funding from Takeda Pharmaceuticals Company Limited, F. Hoffmann-La Roche Ltd and NIH grants R01MH085542, R01MH093725, P50MH066392, P50MH080405, R01MH097276, R01M1H075916, P50MH096891, P50MH084053S1, R37MH057881, AG02219, AG05138, MH06692, R01MH10921, R01MH10677, R01MH109897, U01MH103392, and contract HHSN27120130003I through IRP-NIMH. Brain tissue for the study was obtained from the following brain bank collections: the Mount Sinai NIH Brain and Tissue Repository, the University of Pennsylvania Alzheimer’s Disease Core Center, the University of Pittsburgh NeuroBioBank and Brain and Tissue Repositories, and the NIMH Human Brain Collection Core. CMC Leadership: Panos Roussos, Joseph Buxbaum, Andrew Chess, Schahram Akbarian, Vahram Haroutunian (Icahn School of Medicine at Mount Sinai), Bernie Devlin, David Lewis (University of Pittsburgh), Raquel Gur, Chang-Gyu Hahn (University of Pennsylvania), Enrico Domenici (University of Trento), Mette A. Peters, Solveig Sieberts (Sage BioNetworks), Thomas Lehner, Geetha Senthil, Stefano Marenco, Barbara K. Lipska (NIMH). SKS, TP, KKD, JE, AKG, LO, BAL, and LMM were additionally supported by NIA grants U24 AG61340, U01 AG46170, U01 AG 46161, R01 AG46171, R01 AG 46174. All data used in this manuscript have been previously released.
through their respective consortia and have been reviewed by IRBs at their institution of origin. Informed consent has been obtained from all individuals.

**Author contributions**

S.K.S., S.M., M.P., P.L.D.J., N.E.T. and L.M.M., the AMP-AD Consortium, and the CMC Consortium contributed to the design and generation of the study data. S.K.S., T.P., M.C., M.A., J.S.R., G.H., K.D.D., J.C., P.J.E. and J.E. contributed the data analysis. S.K.S., T.P., G.H., A.K.G., L.O., M.P., B.A.L., L.M.M. contributed to the manuscript preparation and data sharing.

**Competing interests**

The authors declare no competing interests.

**Additional information**

Supplementary information is available for this paper at https://doi.org/10.1038/s41597-020-00642-8.

Correspondence and requests for materials should be addressed to S.K.S. or L.M.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020

**The CommonMind Consortium (CMC)**

Schahram Akbarian11, Jaroslav BendII12, Michael S. Breen13, Kristen Brennand12, Leanne Brown11, Andrew Browne12,14, Joseph D. Buxbaum12,13,14, Alexander Charney12, Andrew Chess15,16,17, Lizette Couto11, Greg Crawford18,19, Olivia Devillers11, Bernie Devlin16, Amanda Dobbny12,21, Enrico Domenici22, Michele Filosi22, Elie Flatow11, Nancy Franceour21, John Fullard12,21, Sergio Espeso Gil11, Kiran Girdhar12, Attila Gulyás-Kovács16, Raquel Gur12, Chang-Gyu Hahn16, Vahram Haroutunian12,17, Mads Engel Hauberg12,25, Laura Hukkins12, Rivky Jacobov11, Yan Jiang11, Jessica S. Johnson12, Bibi Kassim11, Yungil Kim12, Lambertus Klei20, Robin Kramer16, Mario Lauria22, Thomas Lehner18, David A. Lewis19, Barbara K. Lipska16, Kelsey Montgomery17, Royce Park11, Chaggai Rosenbluh16, Panagiotis Roussos13,14,15,29, Douglas M. Ruderfer30, Geetha Senthil28, Hardik R. Shah14, Laura Sloofman12, Lingyun Song18, Eli Stahl12, Patrick Sullivan31, Roberto Visintainer22, Jiebiao Wang12, Ying-Chih Wang15, Jennifer Wiseman11, Eva Xia21, Wen Zhang12 & Elizabeth Zharovsky11

11Division of Psychiatric Epigenomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 12Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 13Seaver Autism for Research and Treatment, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 14Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 15Institute for Genomics and Multiscale Biology, Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 16Department of Cell, Developmental and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 17Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 18Center for Genomic & Computational Biology, Duke University, Durham, North Carolina, USA. 19Division of Medical Genetics, Department of Pediatrics, Duke University, Durham, North Carolina, USA. 20Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. 21Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 22Laboratory of Neurogenomic Biomarkers, Centre for Integrative Biology (CIBIO), University of Trento, Trento, Italy. 23Neuropsychiatry Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 24Neuropsychiatric Signaling Program, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 25Department of Biomedicine, Aarhus University, Aarhus, Denmark. 26Human Brain Collection Core, National Institutes of Health, NIH, Bethesda, Maryland, USA. 27Department of Mathematics, University of Trento, Trento, Italy. 28National Institute of Mental Health, Bethesda, Maryland, USA. 29Psychiatry, JI Peters VA Medical Center, Bronx, New York, USA. 30Department of Medicine, Psychiatry and Biomedical Informatics, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, Tennessee,
USA. 31Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 32Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

The AMP-AD Consortium

Laura Addis5, Sadiya N. Addo33, David Charles Airey5, Matthias Arnold34, David A. Bennett25, Yingtao Bi33, Knut Biber33, Colette Blach36, Elizabeth Bradshaw9, Paul Brennan37, Rosa Canet-Aviles38, Sherry Cao33, Anna Cavalla3, Yoorree Chae3, William W. Chen39, Jie Cheng33, David Andrew Collier9, Jeffrey L. Dage5, Eric B. Dammer30, Justin Wade Davis33, John Davis37, Derek Drake44, Duc Duong40, Brian J. Eastwood9, Michelle Ehrlich21, Benjamin Ellingson33, Brett W. Engelmann33, Sahar Esmaeelineh33, Daniel Felsky9, Cory Funk42, Chris Gaiteri35, Samuel Gandy43, Fan Gao44, Opher Gilead37, Todd Golde45, Shaun E. Grosskurth33, Rishi R. Gupta33, Alex X. Gutteridge46, Vahram Haroutunian32,37, Basavaraj Hooli3, Neil Humphries-Kirilov5, Koichi Iijima47, Corey James5, Paul M. Jung33, Rima Kaddurah-Daouk36, Gabi Kastenmüller34, Hans-Ulrich Klein9, Markus Kummer33, Pascale N. Lacor5, James Lah50, Emma Laing9, Allan Levey40, Yupeng Li5, Samantha Lipsky33, Yushi Liu5, Jimmy Liu39, Zhandong Liu48, Gregory Louie16, Tao Lu41, Yiyi Ma9, Yasuji Y. Matsuoka46, Vilas Menon9, Bradley Miller5, Thomas P. Misko33, Jennifer E. Mollon33, Kelsey Montgomery3, Sumit Mukherjee1, Scott Noggle49, Ping-Chieh Pao44, Tracy Young Pearce40, Neil Pearson5, Michelle Penny39, Vladislav A. Petyuk53, Nathan Price22, Danjuma X. Quarless33, Brinda Ravikumar33, Janina S. Ried33, Cara Lee Ann Ruble5, Heiko Runz39, Andrew J. Saykin52, Eric Schadt21, James E. Scherschel3, Nicholas Seyfried40, Joshua M. Shulman48, Phil Snyder3, Holly Soares33, Gyan P. Srivastava39, Henning Stockmann33, Mariko Taga9, Shinya Tasaki35, Jessie Tenenbaum36, Li-Huei Tsai44, Aparna Vasanthakumar33, Astrid Wachtler33, Yaming Wang5, Minghui Wang21, Christopher D. Whelan39, Charles White53, Kara H. Woo1, Paul Wren46, Jessica W. Wu33, Hualin S. Xi23, Bruce A. Yankner41, Steven G. Younkin2, Lei Yu35, Maria Zavodszyk39, Wenling Zhang5, Guoqiang Zhang39, Bin Zhang21 & Jun Zhu21

33AbbVie Inc, Chicago, IL, USA. 34Helmholtz Zentrum München, Neuherberg, Germany. 35Rush Alzheimer’s Disease Center, Rush University Medical Center, Chicago, IL, USA. 36Duke University, Durham, NC, USA. 37Nuffield Department of Medicine, Oxford University, Headington, UK. 38Foundation for the National Institutes of Health (FNIH), Bethesda, MD, USA. 39Biogen Inc, Cambridge, MA, USA. 40Emory University, Atlanta, GA, USA. 41Department of Genetics, Harvard Medical School, Boston, MA, USA. 42Institute for Systems Biology, Seattle, WA, USA. 43Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 44Picower Institute, Massachusetts Institute of Technology, Cambridge, MA, USA. 45Department of Neuroscience, University of Florida, Gainesville, FL, USA. 46GlaxoSmithKline, Brentford, UK. 47National Center for Geriatrics and Gerontology, Nagoya, Japan. 48Baylor College of Medicine, Houston, TX, USA. 49New York Stem Cell Foundation, New York, NY, USA. 50Brigham & Women’s Hospital, Boston, MA, USA. 51Pacific Northwest National Laboratory, Richland, WA, USA. 52Indiana University School of Medicine, Indianapolis, IN, USA. 53Broad Institute, Cambridge, MA, USA.